Aboul-Enein Mohamed N, El-Azzouny Aida A, Attia Mohamed I, Maklad Yousreya A, Aboutabl Mona E, Ragab Fatma, Abd El-Hamid Walaa H A
Medicinal and Pharmaceutical Chemistry Department (Medicinal Chemistry Group), Pharmaceutical and Drug Industries Research Division, National Research Centre, Dokki, Giza 12622, Egypt.
Medicinal and Pharmaceutical Chemistry Department (Pharmacology Group) Pharmaceutical and Drug Industries Research Division, National Research Centre, Dokki, Giza 12622, Egypt.
Int J Mol Sci. 2014 Sep 23;15(9):16911-35. doi: 10.3390/ijms150916911.
Synthesis and anticonvulsant potential of certain new 6-aryl-9-substituted-6,9-diazaspiro[4.5]decane-8,10-diones (6a-l) and 1-aryl-4-substituted-1,4-diazaspiro[5.5] undecane-3,5-diones (6m-x) are reported. The intermediates 1-[(aryl)(cyanomethyl)amino] cycloalkanecarboxamides (3a-f) were prepared via adopting Strecker synthesis on the proper cycloalkanone followed by partial hydrolysis of the obtained nitrile functionality and subsequent N-cyanomethylation. Compounds 3a-f were subjected to complete nitrile hydrolysis to give the respective carboxylic acid derivatives 4a-f which were cyclized under mild conditions to give the spiro compounds 5a-f. Ultimately, compounds 5a-f were alkylated or aralkylated to give the target compounds 6a-i and 6m-u. On the other hand, compounds 6j-l and 6v-x were synthesized from the intermediates 5a-f through alkylation, dehydration and finally tetrazole ring formation. Anticonvulsant screening of the target compounds 6a-x revealed that compound 6g showed an ED50 of 0.0043 mmol/kg in the scPTZ screen, being about 14 and 214 fold more potent than the reference drugs, Phenobarbital (ED50 = 0.06 mmol/kg) and Ethosuximide (ED50 = 0.92 mmol/kg), respectively. Compound 6e exhibited an ED50 of 0.019 mmol/kg, being about 1.8 fold more potent than that of the reference drug, Diphenylhydantoin (ED50 = 0.034 mmol/kg) in the MES screen. Interestingly, all the test compounds 6a-x did not show any minimal motor impairment at the maximum administered dose in the neurotoxicity screen.
报道了某些新型6-芳基-9-取代-6,9-二氮杂螺[4.5]癸烷-8,10-二酮(6a-l)和1-芳基-4-取代-1,4-二氮杂螺[5.5]十一烷-3,5-二酮(6m-x)的合成及其抗惊厥潜力。中间体1-[(芳基)(氰基甲基)氨基]环烷甲酰胺(3a-f)是通过在适当的环烷酮上采用斯特雷克合成法制备的,然后将所得腈官能团部分水解,随后进行N-氰基甲基化。将化合物3a-f进行完全腈水解,得到相应的羧酸衍生物4a-f,将其在温和条件下环化得到螺环化合物5a-f。最终,将化合物5a-f进行烷基化或芳烷基化,得到目标化合物6a-i和6m-u。另一方面,化合物6j-l和6v-x由中间体5a-f通过烷基化、脱水并最终形成四唑环合成。对目标化合物6a-x的抗惊厥筛选显示,化合物6g在皮下注射戊四氮(scPTZ)筛选中显示的半数有效剂量(ED50)为0.0043 mmol/kg,分别比参考药物苯巴比妥(ED50 = 0.06 mmol/kg)和乙琥胺(ED50 = 0.92 mmol/kg)强约14倍和214倍。化合物6e在最大电休克(MES)筛选中显示的ED50为0.019 mmol/kg,比参考药物苯妥英(ED50 = 0.034 mmol/kg)强约1.8倍。有趣的是,在神经毒性筛选中,所有测试化合物6a-x在最大给药剂量下均未显示任何最小运动损伤。